Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Edwards Lifesciences Corporation (EW : NYSE)

• Company Description    Edwards Lifesciences Corporation deals in products and technologies aimed at treating advanced cardiovascular diseases, especially structural heart disease in critically ill patients. The company is the world's leading manufacturer of tissue heart valves and repair products used to replace or repair a patient's diseased or defective heart valve. Edwards is also a leading player in hemodynamic monitoring systems used to measure a patient's cardiovascular function in the hospital setting. The company's products and technologies are categorized into four main areas: Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), Surgical Structural Heart, and Critical Care. Number of Employees: 15,800

• Price / Volume Information    Yesterday's Closing Price: $85.25 Daily Weekly Monthly 20 Day Moving Average: 2,601,638 shares Shares Outstanding: 580.30 (millions) Market Capitalization: $49,470.58 (millions) Beta: 0.95 52 Week High: $87.89 52 Week Low: $65.94 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -0.62% -0.45% 12 Week 13.38% 11.55% Year To Date 0.00% 0.00%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL ONE EDWARDS WAY - IRVINE,CA 92614 USA ph: 949-250-2500 fax: 949-250-2525 investor_relations@edwards.com http://www.edwards.com

• General Corporate Information    Officers Bernard J. Zovighian - Chief Executive Officer;Director Nicholas J. Valeriani - Chairman of the Board Scott B. Ullem - Chief Financial Officer;Corporate Vice President Andrew M. Dahl - Senior Vice President; Corporate Controller Leslie C. Davis - Director Peer Information Edwards Lifesciences Corporation (ABMD) Edwards Lifesciences Corporation (DMDS) Edwards Lifesciences Corporation (CPWY.) Edwards Lifesciences Corporation (EQUR) Edwards Lifesciences Corporation (ECIA) Edwards Lifesciences Corporation (FMS) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED INSTRUMENTS Sector: Medical CUSIP: 28176E108 SIC: 3842 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 02/10/26 Share - Related Items Shares Outstanding: 580.30 Most Recent Split Date: 6.00 (3.00:1) Beta: 0.95 Market Capitalization: $49,470.58 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $0.67 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $2.86 Payout Ratio: 0.00 Number of Estimates in the Fiscal Year Consensus: 11.00 Change In Payout Ratio: 0.00 Estmated Long-Term EPS Growth Rate: 8.59% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 02/10/26

• Fundamental Ratios P/E Current FY Estimate: 29.76 Trailing 12 Months: 33.17 PEG Ratio: 3.46 Price Ratios Price/Book: 4.90 Price/Cash Flow: 31.22 Price / Sales: 8.41 EPS Growth vs. Year Ago Period: 0.00% vs. Previous Quarter: 0.00% Sales Growth vs. Year Ago Period: 14.67% vs. Previous Quarter: 1.36% ROE 12/31/25 - - 09/30/25 - 14.70 06/30/25 - 15.01 ROA 12/31/25 - - 09/30/25 - 11.43 06/30/25 - 11.56 Current Ratio 12/31/25 - - 09/30/25 - 4.00 06/30/25 - 4.68 Quick Ratio 12/31/25 - - 09/30/25 - 3.29 06/30/25 - 3.87 Operating Margin 12/31/25 - - 09/30/25 - 25.66 06/30/25 - 26.71 Net Margin 12/31/25 - - 09/30/25 - 23.25 06/30/25 - 72.96 Pre-Tax Margin 12/31/25 - - 09/30/25 - 26.73 06/30/25 - 28.62 Book Value 12/31/25 - - 09/30/25 - 17.38 06/30/25 - 18.08 Inventory Turnover 12/31/25 - - 09/30/25 - 1.15 06/30/25 - 1.08 Debt-to-Equity 12/31/25 - - 09/30/25 - 0.06 06/30/25 - 0.06 Debt-to-Capital 12/31/25 - - 09/30/25 - 5.54 06/30/25 - 5.34

Powered by Zacks Investment Research ©